Seven Eight Capital’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-90,195
| Closed | -$5.95M | – | 207 |
|
|
2024
Q3 | $5.95M | Buy |
+90,195
| New | +$6.55M | 0.53% | 16 |
|
|
2024
Q2 | – | Sell |
-17,613
| Closed | -$1.68M | – | 759 |
|
|
2024
Q1 | $1.68M | Buy |
17,613
+441
| +3% | +$37K | 0.18% | 174 |
|
|
2023
Q4 | $1.31M | Sell |
17,172
-159,956
| -90% | -$11.1M | 0.15% | 198 |
|
|
2023
Q3 | $12.3M | Buy |
177,128
+169,746
| +2,299% | +$13.6M | 1.44% | 1 |
|
|
2023
Q2 | $696K | Sell |
7,382
-20,930
| -74% | -$1.82M | 0.12% | 243 |
|
|
2023
Q1 | $2.34M | Buy |
28,312
+9,625
| +52% | +$757K | 0.49% | 45 |
|
|
2022
Q4 | $1.39M | Sell |
18,687
-78,117
| -81% | -$6.02M | 0.36% | 83 |
|
|
2022
Q3 | $7.88M | Buy |
+96,804
| New | +$9.31M | 1.58% | 1 |
|
|
2022
Q2 | – | Sell |
-3,228
| Closed | -$380K | – | 452 |
|
|
2022
Q1 | $380K | Buy |
+3,228
| New | +$362K | 0.05% | 367 |
|
|
2021
Q4 | – | Sell |
-27,124
| Closed | -$3.07M | – | 533 |
|
|
2021
Q3 | $3.07M | Buy |
27,124
+13,300
| +96% | +$1.52M | 0.3% | 104 |
|
|
2021
Q2 | $1.43M | Buy |
+13,824
| New | +$1.3M | 0.2% | 167 |
|
|
2020
Q4 | – | Sell |
-6,200
| Closed | -$495K | – | 477 |
|
|
2020
Q3 | $495K | Sell |
6,200
-7,200
| -54% | -$562K | 0.11% | 342 |
|
|
2020
Q2 | $939K | Sell |
13,400
-35,200
| -72% | -$2.5M | 0.69% | 22 |
|
|
2020
Q1 | $3.06M | Sell |
48,600
-121,587
| -71% | -$8.77M | 0.79% | 23 |
|
|
2019
Q4 | $13.2M | Buy |
170,187
+110,700
| +186% | +$8.64M | 0.7% | 16 |
|
|
2019
Q3 | $4.36M | Buy |
+59,487
| New | +$4.18M | 0.23% | 125 |
|
|
2019
Q2 | – | Sell |
-144,087
| Closed | -$9.19M | – | 631 |
|
|
2019
Q1 | $9.19M | Buy |
+144,087
| New | +$8.22M | 0.49% | 53 |
|
|
2018
Q1 | – | Sell |
-141,987
| Closed | -$5.33M | – | 418 |
|
|
2017
Q4 | $5.33M | Buy |
141,987
+10,176
| +8% | +$373K | 0.54% | 45 |
|
|
2017
Q3 | $4.8M | Buy |
+131,811
| New | +$5.03M | 0.59% | 45 |
|
|
2017
Q2 | – | Sell |
-39,111
| Closed | -$1.23M | – | 593 |
|
|
2017
Q1 | $1.23M | Sell |
39,111
-12,444
| -24% | -$390K | 0.24% | 148 |
|
|
2016
Q4 | $1.61M | Buy |
+51,555
| New | +$1.67M | 0.32% | 101 |
|
|
2016
Q3 | – | Sell |
-76,800
| Closed | -$2.55M | – | 407 |
|
|
2016
Q2 | $2.55M | Buy |
76,800
+49,200
| +178% | +$1.68M | 0.88% | 14 |
|
|
2016
Q1 | $812K | Buy |
27,600
+14,400
| +109% | +$397K | 0.35% | 99 |
|
|
2015
Q4 | $348K | Buy |
+13,200
| New | +$343K | 0.24% | 151 |
|
|
2015
Q3 | – | Sell |
-4,800
| Closed | -$114K | – | 577 |
|
|
2015
Q2 | $114K | Buy |
4,800
+4,200
| +700% | +$94.8K | 0.13% | 248 |
|
|
2015
Q1 | $14K | Buy |
+600
| New | +$13.5K | 0.02% | 376 |
|
|
2014
Q2 | – | Sell |
-31,200
| Closed | -$386K | – | 540 |
|
|
2014
Q1 | $386K | Buy |
+31,200
| New | +$360K | 0.33% | 105 |
|
Other funds holding EW
Seven Eight Capital's EW Position: Q4 2024 in Review
Seven Eight Capital sold out of Edwards Lifesciences (EW) in Q4 2024, closing a stake of 90,195 shares — an estimated $5.95M sold.
Seven Eight Capital first reported a position in EW in Q1 2014 and held it in 27 quarters. The position peaked at $13.2M in Q4 2019. 1,226 funds tracked by Wall St. Rank hold EW as of Q4 2024.
- Seven Eight Capital reported no remaining Edwards Lifesciences position as of Q4 2024 after selling out during the quarter.
- Seven Eight Capital sold 90,195 Edwards Lifesciences shares in Q4 2024, an estimated $5.95M.
- Seven Eight Capital first reported a position in Edwards Lifesciences in Q1 2014 and held it in 27 quarters.
- Seven Eight Capital's Edwards Lifesciences position peaked at $13.2M in Q4 2019.
- 1,226 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.
Based on Seven Eight Capital's 13F filing for Q4 2024.